Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

202.66USD
9:01pm BST
Change (% chg)

$-7.34 (-3.50%)
Prev Close
$210.00
Open
$208.31
Day's High
$208.40
Day's Low
$202.60
Volume
1,138,693
Avg. Vol
503,835
52-wk High
$256.78
52-wk Low
$184.58

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $70,204.30
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.33

Financials

  Industry Sector
P/E (TTM): -- 31.16 16.22
EPS (TTM): -- -- --
ROI: -- 14.31 15.23
ROE: -- 15.64 13.84

U.S. senator slams Allergan patent deal with Native-American tribe

U.S. Senator Sherrod Brown said on Friday a deal that drugmaker Allergan Plc made with a Native-American tribe to shield patents "rips off consumers" and cannot "become the new normal."

15 Sep 2017

UPDATE 2-U.S. senator slams Allergan patent deal with Native-American tribe

Sept 15 U.S. Senator Sherrod Brown said on Friday a deal that drugmaker Allergan Plc made with a Native-American tribe to shield patents "rips off consumers" and cannot "become the new normal."

15 Sep 2017

U.S. senator slams Allergan tribal patent deal

Sept 15 U.S. Senator Sherrod Brown said on Friday a deal Allergan Plc made with a Native American tribe to shield its patents "rips off consumers" and cannot "become the new normal."

15 Sep 2017

REFILE-Challenge of Allergan tribal patent deal in uncharted legal territory

(Fixes date in dateline) By Jan Wolfe Sept 14 As generic drug manufacturers are gearing up to argue that a deal Allergan Plc made with a Native American tribe to shield patents from administrative review is a sham, some experts say the generic companies are in uncharted legal territory. Last week, Allergan announced it would transfer the patent rights to its Restasis dry-eye treatment to the Saint Regis Mohawk Tribe, which will license them back to the company i

14 Sep 2017

Challenge of Allergan tribal patent deal in uncharted legal territory

As generic drug manufacturers are gearing up to argue that a deal Allergan Plc made with a Native American tribe to shield patents from administrative review is a sham, some experts say the generic companies are in uncharted legal territory.

14 Sep 2017

Tech entity has tribal patent deal similar to Allergan's

The Native American tribe that agreed to hold patents for the drug company Allergan Plc in an attempt to shield them from U.S. administrative review is also doing so for a technology firm.

13 Sep 2017

Tech entity has tribal patent deal similar to Allergan's

Sept 12 The Native American tribe that agreed to hold patents for the drug company Allergan Plc in an attempt to shield them from U.S. administrative review is also doing so for a technology firm.

12 Sep 2017

Mylan says Allergan misusing tribal sovereignty in patent dispute

NEW YORK Generic drugmaker Mylan NV alleged in a court filing that rival Allergan Plc is trying to take advantage of Native American sovereignty to shield its patent for the blockbuster dry-eye treatment Restasis.

12 Sep 2017

Mylan says Allergan misusing tribal sovereignty in patent dispute

NEW YORK, Sept 12 Generic drugmaker Mylan NV alleged in a court filing that rival Allergan Plc is trying to take advantage of Native American sovereignty to shield its patent for the blockbuster dry-eye treatment Restasis.

12 Sep 2017

BRIEF-Imprimis Pharmaceuticals ‍responded to Allergan Plc press release regarding lawsuit

* Imprimis Pharmaceuticals Inc - ‍responded to a press release issued by Allergan Plc regarding a lawsuit Allergan USA, Inc. filed against Imprimis​

11 Sep 2017

Earnings vs. Estimates